Pricing
  1. JP-listed companies
  2. RIBOMIC Inc.
  3. Financials
  4. Pretax margin (%)

RIBOMIC Inc.【JP:4591】

Market cap
¥4.4B
P/E ratio
-3.8x
Ribomics develops next-generation aptamer drugs using its proprietary RiboART System to treat unmet medical needs like achondroplasia and eye diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Mar 31, 2025-48,166.2+1826.55%
Mar 31, 2023-2,500.1+23.68%
Mar 31, 2022-2,021.4+56.88%
Mar 31, 2021-1,288.6+83.19%
Mar 31, 2020-703.4-93.31%
Mar 31, 2019-10,507+804.84%
Mar 31, 2018-1,161.2+65.27%
Mar 31, 2017-702.6+165.93%
Mar 31, 2016-264.2-9708.75%
Mar 31, 20152.7-101.97%
Mar 31, 2014-139.5-14.59%
Mar 31, 2013-163.3+19.70%
Mar 31, 2012-136.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)